Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology, Surgical | 4 | 2023 | 155 | 3.020 |
Why?
|
| Laboratories | 4 | 2022 | 463 | 1.850 |
Why?
|
| Quality Assurance, Health Care | 6 | 2022 | 2212 | 1.510 |
Why?
|
| Cytodiagnosis | 3 | 2020 | 435 | 1.490 |
Why?
|
| Diagnostic Errors | 7 | 2023 | 1257 | 1.400 |
Why?
|
| Specimen Handling | 5 | 2022 | 694 | 1.310 |
Why?
|
| Laboratories, Hospital | 2 | 2019 | 194 | 1.120 |
Why?
|
| Medical Errors | 3 | 2019 | 1297 | 1.020 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2022 | 104 | 0.790 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2019 | 30 | 0.690 |
Why?
|
| False Positive Reactions | 2 | 2019 | 981 | 0.690 |
Why?
|
| Total Quality Management | 1 | 2020 | 274 | 0.670 |
Why?
|
| Pathology, Clinical | 1 | 2022 | 368 | 0.650 |
Why?
|
| Frozen Sections | 1 | 2019 | 155 | 0.650 |
Why?
|
| Histological Techniques | 1 | 2016 | 198 | 0.560 |
Why?
|
| Quality Improvement | 4 | 2021 | 3749 | 0.550 |
Why?
|
| Chondrosarcoma | 1 | 2018 | 309 | 0.550 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2016 | 108 | 0.540 |
Why?
|
| Checklist | 2 | 2020 | 833 | 0.520 |
Why?
|
| Pathology | 1 | 2018 | 272 | 0.500 |
Why?
|
| Thyroid Gland | 2 | 2020 | 1173 | 0.480 |
Why?
|
| Truth Disclosure | 1 | 2018 | 436 | 0.470 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2018 | 602 | 0.450 |
Why?
|
| Lymphatic Metastasis | 2 | 2018 | 2924 | 0.430 |
Why?
|
| Models, Theoretical | 1 | 2020 | 3589 | 0.310 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2009 | 1101 | 0.310 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2727 | 0.300 |
Why?
|
| Genes, BRCA2 | 1 | 2009 | 618 | 0.270 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 2 | 2012 | 42 | 0.270 |
Why?
|
| Kidney | 4 | 2013 | 7186 | 0.230 |
Why?
|
| Kidney Transplantation | 3 | 2013 | 4251 | 0.220 |
Why?
|
| Complement C4b | 1 | 2013 | 135 | 0.220 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2018 | 5221 | 0.210 |
Why?
|
| Plasma Cell Granuloma, Pulmonary | 1 | 2010 | 13 | 0.190 |
Why?
|
| Adenovirus Infections, Human | 1 | 2011 | 71 | 0.190 |
Why?
|
| Planning Techniques | 1 | 2020 | 82 | 0.190 |
Why?
|
| Pancreas Transplantation | 1 | 2011 | 187 | 0.180 |
Why?
|
| Cryptococcosis | 1 | 2010 | 101 | 0.170 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2009 | 102 | 0.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2023 | 2649 | 0.170 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2013 | 357 | 0.170 |
Why?
|
| Lupus Nephritis | 1 | 2012 | 310 | 0.170 |
Why?
|
| Humans | 30 | 2023 | 744343 | 0.170 |
Why?
|
| North Carolina | 1 | 2019 | 315 | 0.160 |
Why?
|
| Ecosystem | 1 | 2023 | 474 | 0.160 |
Why?
|
| Cytological Techniques | 1 | 2020 | 219 | 0.160 |
Why?
|
| Organizational Objectives | 1 | 2020 | 438 | 0.160 |
Why?
|
| Intraoperative Period | 1 | 2019 | 520 | 0.160 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2009 | 111 | 0.160 |
Why?
|
| Esophagitis | 1 | 2009 | 152 | 0.150 |
Why?
|
| Gastroscopy | 1 | 2009 | 207 | 0.150 |
Why?
|
| Polyps | 1 | 2009 | 189 | 0.150 |
Why?
|
| Carcinoma | 2 | 2019 | 2375 | 0.150 |
Why?
|
| Hospitals, University | 1 | 2019 | 571 | 0.150 |
Why?
|
| Adenoviridae | 1 | 2011 | 1099 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13102 | 0.140 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1641 | 0.140 |
Why?
|
| Endometrium | 1 | 2019 | 424 | 0.140 |
Why?
|
| Abdominal Pain | 1 | 2013 | 1063 | 0.140 |
Why?
|
| Risk Management | 1 | 2019 | 571 | 0.130 |
Why?
|
| Fever | 1 | 2013 | 1616 | 0.130 |
Why?
|
| Workflow | 2 | 2017 | 847 | 0.130 |
Why?
|
| Barrett Esophagus | 1 | 2009 | 494 | 0.120 |
Why?
|
| Eosinophilia | 1 | 2009 | 541 | 0.120 |
Why?
|
| Watchful Waiting | 1 | 2018 | 492 | 0.120 |
Why?
|
| Mutation | 1 | 2018 | 29786 | 0.110 |
Why?
|
| Graft Rejection | 2 | 2013 | 4397 | 0.110 |
Why?
|
| DNA Mutational Analysis | 2 | 2018 | 4186 | 0.110 |
Why?
|
| Efficiency, Organizational | 1 | 2016 | 695 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2009 | 782 | 0.100 |
Why?
|
| Hospitals, Teaching | 1 | 2016 | 1179 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 1758 | 0.100 |
Why?
|
| Gastrointestinal Diseases | 1 | 2009 | 1170 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2013 | 5097 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 1 | 2013 | 2538 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2012 | 2104 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1353 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 1972 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2214 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2009 | 1333 | 0.090 |
Why?
|
| Patient Care Team | 1 | 2020 | 2531 | 0.080 |
Why?
|
| Adenoma | 1 | 2009 | 2174 | 0.080 |
Why?
|
| Female | 11 | 2022 | 380194 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 11524 | 0.080 |
Why?
|
| Communication | 1 | 2022 | 3749 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 20822 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 77449 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2019 | 3528 | 0.070 |
Why?
|
| Diagnosis, Differential | 4 | 2012 | 12959 | 0.070 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 4776 | 0.060 |
Why?
|
| Transplantation, Autologous | 1 | 2009 | 2124 | 0.060 |
Why?
|
| Mastectomy, Segmental | 1 | 2009 | 956 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2017 | 3444 | 0.060 |
Why?
|
| Boston | 1 | 2016 | 9313 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 19905 | 0.060 |
Why?
|
| Immunohistochemistry | 3 | 2013 | 11366 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2019 | 4838 | 0.050 |
Why?
|
| Pedigree | 1 | 2009 | 4644 | 0.050 |
Why?
|
| Prognosis | 2 | 2018 | 29063 | 0.050 |
Why?
|
| Radiography | 2 | 2012 | 7023 | 0.050 |
Why?
|
| Hematuria | 1 | 2012 | 235 | 0.050 |
Why?
|
| Cryptococcus gattii | 1 | 2010 | 2 | 0.050 |
Why?
|
| Glomerulonephritis | 1 | 2012 | 372 | 0.050 |
Why?
|
| Time Factors | 2 | 2019 | 40075 | 0.040 |
Why?
|
| Fluconazole | 1 | 2010 | 146 | 0.040 |
Why?
|
| Middle Aged | 4 | 2022 | 213383 | 0.040 |
Why?
|
| Pulmonary Alveoli | 1 | 2012 | 675 | 0.040 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2012 | 220 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 53288 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2011 | 15295 | 0.040 |
Why?
|
| Edema | 1 | 2012 | 789 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 214055 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 8642 | 0.040 |
Why?
|
| Aged | 5 | 2019 | 163280 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 2529 | 0.040 |
Why?
|
| Observer Variation | 1 | 2013 | 2593 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 804 | 0.040 |
Why?
|
| Genetic Techniques | 1 | 2009 | 435 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2009 | 527 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2009 | 1950 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2010 | 730 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 1035 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2009 | 600 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2010 | 1094 | 0.030 |
Why?
|
| Male | 7 | 2017 | 350118 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2012 | 5179 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2012 | 2035 | 0.030 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 1199 | 0.030 |
Why?
|
| Antibodies | 1 | 2012 | 2460 | 0.030 |
Why?
|
| Lung | 2 | 2012 | 9856 | 0.030 |
Why?
|
| Thyroidectomy | 1 | 2009 | 879 | 0.030 |
Why?
|
| Esophagus | 1 | 2009 | 1019 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2009 | 868 | 0.030 |
Why?
|
| Lung Diseases | 1 | 2012 | 1886 | 0.030 |
Why?
|
| Causality | 1 | 2009 | 1275 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2009 | 1547 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 3920 | 0.020 |
Why?
|
| Biopsy | 1 | 2013 | 6756 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2012 | 3461 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1692 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1660 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2017 | 2455 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5078 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2009 | 5985 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 5319 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4554 | 0.020 |
Why?
|
| Comorbidity | 1 | 2009 | 10388 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 56430 | 0.010 |
Why?
|
| Prevalence | 1 | 2009 | 15226 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20129 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7279 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 57776 | 0.010 |
Why?
|
| Adolescent | 1 | 2009 | 85781 | 0.010 |
Why?
|
Concepts
(153)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_